Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells

Alexandra P Z Vieira, Noriyuki Kasahara, Angelo Cardoso, Vinod Pullarkat, Alexandra M. Levine, Renata Stripecke

Research output: Contribution to journalArticle

Abstract

Leukemia cells genetically modified to express immunomodulators such as CD80 have been shown to stimulate the ex vivo proliferation of human autologous anti-leukemia reactive T cells and induce a protective effect against leukemia challenge in animal models in vivo. These results led us to further characterize the effect of other immunostimulatory genes that, when co-expressed by leukemia cells, may further enhance the antigen presentation through MHC class 1 and class 11 pathways. It was recently shown that second generation HIV-derived lentiviral vectors (lacking vpr, vpu, vif and nef) expressing CD80 and/or GMCSF can efficiently transduce primary Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) cells (40-100% CD80 positive) and promote stable and high levels of expression (Blood. 2000; 96:1317-1326). In the present studies, we have evaluated a safer, third generation self-inactivating HIV vector system (lacking tat and the original HIV LTR), kindly provided by L. Naldini et al (University of Torino, Italy), to deliver GMCSF, CD80, IL-4 and CD40L into leukemia cells. The produced vectors were concentrated to high titers (10E8 particles/ml) and successfully expressed the transgenes, as assayed by F ACS (CD80, CD40L) and EL1SA (GM-CSF, IL-4). Primary leukemia cells transduced with third generation vectors will be used to stimulate autologous effector cells obtained from AML patients during remission in Mixed Lymphocyte Reactions (MLR). The autocrine and paracrine effects of the expression of the transgenes on antigen presentation in AML cells will be also evaluated. Finally, the lentivirally transduced AML are expected to provide a potent activation of T-, B- and dendritic cells that can be explored for ex vivo expansion of autologous anti-AML effector cells and for clinical vaccination procedures.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART II
StatePublished - 2000
Externally publishedYes

Fingerprint

Myeloid Cells
Acute Myeloid Leukemia
CD40 Ligand
Leukemia
Interleukin-4
Antigens
Antigen Presentation
HIV
T-cells
Lymphocytes
Transgenes
Immunologic Factors
Granulocyte-Macrophage Colony-Stimulating Factor
Animals
Blood
Genes
T-Cell Leukemia
Chemical activation
Mixed Lymphocyte Culture Test
Precursor Cell Lymphoblastic Leukemia-Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Vieira, A. P. Z., Kasahara, N., Cardoso, A., Pullarkat, V., Levine, A. M., & Stripecke, R. (2000). Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells. Blood, 96(11 PART II).

Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells. / Vieira, Alexandra P Z; Kasahara, Noriyuki; Cardoso, Angelo; Pullarkat, Vinod; Levine, Alexandra M.; Stripecke, Renata.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Vieira, APZ, Kasahara, N, Cardoso, A, Pullarkat, V, Levine, AM & Stripecke, R 2000, 'Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells', Blood, vol. 96, no. 11 PART II.
Vieira APZ, Kasahara N, Cardoso A, Pullarkat V, Levine AM, Stripecke R. Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells. Blood. 2000;96(11 PART II).
Vieira, Alexandra P Z ; Kasahara, Noriyuki ; Cardoso, Angelo ; Pullarkat, Vinod ; Levine, Alexandra M. ; Stripecke, Renata. / Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{3e7a4eb7853649e4bc2f8d49a7222526,
title = "Third generation lentiviral vectors to {"}boost{"} an immune response against acute myeloid leukemia cells",
abstract = "Leukemia cells genetically modified to express immunomodulators such as CD80 have been shown to stimulate the ex vivo proliferation of human autologous anti-leukemia reactive T cells and induce a protective effect against leukemia challenge in animal models in vivo. These results led us to further characterize the effect of other immunostimulatory genes that, when co-expressed by leukemia cells, may further enhance the antigen presentation through MHC class 1 and class 11 pathways. It was recently shown that second generation HIV-derived lentiviral vectors (lacking vpr, vpu, vif and nef) expressing CD80 and/or GMCSF can efficiently transduce primary Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) cells (40-100{\%} CD80 positive) and promote stable and high levels of expression (Blood. 2000; 96:1317-1326). In the present studies, we have evaluated a safer, third generation self-inactivating HIV vector system (lacking tat and the original HIV LTR), kindly provided by L. Naldini et al (University of Torino, Italy), to deliver GMCSF, CD80, IL-4 and CD40L into leukemia cells. The produced vectors were concentrated to high titers (10E8 particles/ml) and successfully expressed the transgenes, as assayed by F ACS (CD80, CD40L) and EL1SA (GM-CSF, IL-4). Primary leukemia cells transduced with third generation vectors will be used to stimulate autologous effector cells obtained from AML patients during remission in Mixed Lymphocyte Reactions (MLR). The autocrine and paracrine effects of the expression of the transgenes on antigen presentation in AML cells will be also evaluated. Finally, the lentivirally transduced AML are expected to provide a potent activation of T-, B- and dendritic cells that can be explored for ex vivo expansion of autologous anti-AML effector cells and for clinical vaccination procedures.",
author = "Vieira, {Alexandra P Z} and Noriyuki Kasahara and Angelo Cardoso and Vinod Pullarkat and Levine, {Alexandra M.} and Renata Stripecke",
year = "2000",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Third generation lentiviral vectors to "boost" an immune response against acute myeloid leukemia cells

AU - Vieira, Alexandra P Z

AU - Kasahara, Noriyuki

AU - Cardoso, Angelo

AU - Pullarkat, Vinod

AU - Levine, Alexandra M.

AU - Stripecke, Renata

PY - 2000

Y1 - 2000

N2 - Leukemia cells genetically modified to express immunomodulators such as CD80 have been shown to stimulate the ex vivo proliferation of human autologous anti-leukemia reactive T cells and induce a protective effect against leukemia challenge in animal models in vivo. These results led us to further characterize the effect of other immunostimulatory genes that, when co-expressed by leukemia cells, may further enhance the antigen presentation through MHC class 1 and class 11 pathways. It was recently shown that second generation HIV-derived lentiviral vectors (lacking vpr, vpu, vif and nef) expressing CD80 and/or GMCSF can efficiently transduce primary Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) cells (40-100% CD80 positive) and promote stable and high levels of expression (Blood. 2000; 96:1317-1326). In the present studies, we have evaluated a safer, third generation self-inactivating HIV vector system (lacking tat and the original HIV LTR), kindly provided by L. Naldini et al (University of Torino, Italy), to deliver GMCSF, CD80, IL-4 and CD40L into leukemia cells. The produced vectors were concentrated to high titers (10E8 particles/ml) and successfully expressed the transgenes, as assayed by F ACS (CD80, CD40L) and EL1SA (GM-CSF, IL-4). Primary leukemia cells transduced with third generation vectors will be used to stimulate autologous effector cells obtained from AML patients during remission in Mixed Lymphocyte Reactions (MLR). The autocrine and paracrine effects of the expression of the transgenes on antigen presentation in AML cells will be also evaluated. Finally, the lentivirally transduced AML are expected to provide a potent activation of T-, B- and dendritic cells that can be explored for ex vivo expansion of autologous anti-AML effector cells and for clinical vaccination procedures.

AB - Leukemia cells genetically modified to express immunomodulators such as CD80 have been shown to stimulate the ex vivo proliferation of human autologous anti-leukemia reactive T cells and induce a protective effect against leukemia challenge in animal models in vivo. These results led us to further characterize the effect of other immunostimulatory genes that, when co-expressed by leukemia cells, may further enhance the antigen presentation through MHC class 1 and class 11 pathways. It was recently shown that second generation HIV-derived lentiviral vectors (lacking vpr, vpu, vif and nef) expressing CD80 and/or GMCSF can efficiently transduce primary Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) cells (40-100% CD80 positive) and promote stable and high levels of expression (Blood. 2000; 96:1317-1326). In the present studies, we have evaluated a safer, third generation self-inactivating HIV vector system (lacking tat and the original HIV LTR), kindly provided by L. Naldini et al (University of Torino, Italy), to deliver GMCSF, CD80, IL-4 and CD40L into leukemia cells. The produced vectors were concentrated to high titers (10E8 particles/ml) and successfully expressed the transgenes, as assayed by F ACS (CD80, CD40L) and EL1SA (GM-CSF, IL-4). Primary leukemia cells transduced with third generation vectors will be used to stimulate autologous effector cells obtained from AML patients during remission in Mixed Lymphocyte Reactions (MLR). The autocrine and paracrine effects of the expression of the transgenes on antigen presentation in AML cells will be also evaluated. Finally, the lentivirally transduced AML are expected to provide a potent activation of T-, B- and dendritic cells that can be explored for ex vivo expansion of autologous anti-AML effector cells and for clinical vaccination procedures.

UR - http://www.scopus.com/inward/record.url?scp=33748521877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748521877&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748521877

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -